Epidemiology of glioma: clinical characteristics, symptoms, and predictors of glioma patients grade I-IV in the the Danish Neuro-Oncology Registry

被引:213
作者
Rasmussen, Birthe Krogh [1 ]
Hansen, Steinbjorn [2 ,3 ]
Laursen, Rene J. [4 ]
Kosteljanetz, Michael [5 ]
Schultz, Henrik [6 ]
Norgard, Bente Mertz [3 ,7 ]
Guldberg, Rikke [3 ,7 ]
Gradel, Kim Oren [3 ,7 ]
机构
[1] Univ Copenhagen, Nordsjaellands Hosp, Dept Neurol, Hillerod, Denmark
[2] Odense Univ Hosp, Dept Oncol, DK-5000 Odense C, Denmark
[3] Univ Southern Denmark, Inst Clin Res, Odense C, Denmark
[4] Aalborg Univ Hosp, Dept Neurosurg, Aalborg, Denmark
[5] Copenhagen Univ Hosp, Dept Neurosurg, Copenhagen, Denmark
[6] Aarhus Univ Hosp, Dept Oncol, Aarhus, Denmark
[7] Odense Univ Hosp, Ctr Clin Epidemiol, Odense C, Denmark
关键词
Glioma; Epidemiology; Symptoms; Prognosis; Survival; TUMORS; DENMARK; CLASSIFICATION; HEADACHES; SURVIVAL; DISEASE; RATES;
D O I
10.1007/s11060-017-2607-5
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
In this national population-based study of glioma, we present epidemiologic data on incidence, demographics, survival, clinical characteristics and symptoms, and evaluate the association of specific indicators with the grade of glioma. We included 1930 patients registered in the Danish Neuro-Oncology Registry (DNOR) from 2009 to 2014. DNOR is a large-scale national population-based database including all adult glioma patients in Denmark. The age-adjusted annual incidence of histologic verified glioma was 7.3 cases pr. 100,000 person-years. High-grade gliomas were present in 85% and low-grade glioma in 15%. The overall male:female ratio was 3:2 and the mean age at onset was 60 years. Data for WHO grade I, II, III and IV glioma showed several important differences regarding age and sex distribution and symptomatology at presentation. The mean age increased with the grade of glioma and males predominated in all grades. Focal deficits were the most frequent presenting symptom, but among patients with glioma, grade II epileptic seizures were the most frequent symptom. Headache was a rare mono-symptomatic onset symptom. At presentation, higher age, focal deficits and cognitive change for < 3 months duration, and headache < 1 month were significant independent indicators of high-grade gliomas. Younger age and epileptic seizures for more than 3 months were indicative for low-grade gliomas. Survival rates for glioma grade I-IV showed decreasing survival with increasing grade. Glioma grade I-IV showed high diversity regarding several demographic and clinical characteristics emphasizing the importance of individually tailored disease treatments and support.
引用
收藏
页码:571 / 579
页数:9
相关论文
共 25 条
  • [21] Surgical management of Glioma Grade 4: technical update from the neuro-oncology section of the Italian Society of Neurosurgery (SINch®): a systematic review
    Tamara Ius
    Giovanni Sabatino
    Pier Paolo Panciani
    Marco Maria Fontanella
    Roberta Rudà
    Antonella Castellano
    Giuseppe Maria Vincenzo Barbagallo
    Francesco Belotti
    Riccardo Boccaletti
    Giuseppe Catapano
    Gabriele Costantino
    Alessandro Della Puppa
    Francesco Di Meco
    Filippo Gagliardi
    Diego Garbossa
    Antonino Francesco Germanò
    Maurizio Iacoangeli
    Pietro Mortini
    Alessandro Olivi
    Federico Pessina
    Fabrizio Pignotti
    Giampietro Pinna
    Antonino Raco
    Francesco Sala
    Francesco Signorelli
    Silvio Sarubbo
    Miran Skrap
    Giannantonio Spena
    Teresa Somma
    Carmelo Sturiale
    Filippo Flavio Angileri
    Vincenzo Esposito
    [J]. Journal of Neuro-Oncology, 2023, 162 : 267 - 293
  • [22] One year of procarbazine lomustine and vincristine is poorly tolerated in low grade glioma: a real world experience in a national neuro-oncology centre
    Rachel J. Keogh
    Razia Aslam
    Maeve A. Hennessy
    Zac Coyne
    Bryan T. Hennessy
    Oscar S. Breathnach
    Liam Grogan
    Patrick G. Morris
    [J]. BMC Cancer, 21
  • [23] Personalized care in neuro-oncology coming of age: why we need MGMT and 1p/19q testing for malignant glioma patients in clinical practice
    Weller, Michael
    Stupp, Roger
    Hegi, Monika E.
    van den Bent, Martin
    Tonn, Joerg C.
    Sanson, Marc
    Wick, Wolfgang
    Reifenberger, Guido
    [J]. NEURO-ONCOLOGY, 2012, 14 : 100 - 108
  • [24] LOGGIC Core BioClinical Data Bank: Added clinical value of RNA-Seq in an international molecular diagnostic registry for pediatric low-grade glioma patients
    Hardin, Emily C.
    Schmid, Simone
    Sommerkamp, Alexander
    Bodden, Carina
    Heipertz, Anna-Elisa
    Sievers, Philipp
    Wittmann, Andrea
    Milde, Till
    Pfister, Stefan M.
    von Deimling, Andreas
    Horn, Svea
    Herz, Nina A.
    Simon, Michele
    Perera, Ashwyn A.
    Azizi, Amedeo
    Cruz, Ofelia
    Curry, Sarah
    Van Damme, An
    Garami, Miklos
    Hargrave, Darren
    Kattamis, Antonis
    Kotnik, Barbara Faganel
    Lahteenmaki, Paivi
    Scheinemann, Katrin
    Schouten-van Meeteren, Antoinette Y. N.
    Sehested, Astrid
    Viscardi, Elisabetta
    Wormdal, Ole Mikal
    Zapotocky, Michal
    Ziegler, David S.
    Koch, Arend
    Driever, Pablo Hernaiz
    Witt, Olaf
    Capper, David
    Sahm, Felix
    Jones, David T. W.
    van Tilburg, Cornelis M.
    [J]. NEURO-ONCOLOGY, 2023, 25 (11) : 2087 - 2097
  • [25] Association of Clinical, Tumor, and Treatment Characteristics With Seizure Control in Patients With IDH1/2-Mutant Lower-Grade Glioma
    Bruno, Francesco
    Pellerino, Alessia
    Conti Nibali, Marco
    Pronello, Edoardo
    Cofano, Fabio
    Rossi, Marco
    Levis, Mario
    Bertero, Luca
    Soffietti, Riccardo
    Cassoni, Paola
    Garbossa, Diego
    Bello, Lorenzo
    Ruda, Roberta
    [J]. NEUROLOGY, 2024, 102 (10)